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Mean savings per patient per year compared to formoterol/budesonide, Salmeterol/
Fluticasone and Tiotropium were of COP 1,593,128.1 (USD822.9), COP 2,366,779.1 (USD 
1,222.6) and COP 8,990.6 (USD4,64). The probabilistic sensitivity analysis presented 
Glycopirronium as a dominant alternative compared to tiotroprium and formoterol/
budesonide in more than 90% of the cases and against salmeterol/fluticasone the 
results were inconclusive. ConClusions: Glycopirronium is cost-effective when 
compared to other long-acting bronchodilators in the Colombian Health Care System.
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objeCtives: This study evaluated the cost-effectiveness of Indacaterol (150 ug) ver-
sus Tiotropium applied to the patients with Chronic obstructive pulmonary disease 
(COPD) in Guangzhou, China. Methods: Markov model was developed to simulate 
the progress of COPD for 3 years and whole life respectively. The transfer probability in 
the Markov model and the utility of different Markov status were from the Indacaterol 
‘s clinical trial conducted in the US. Medical cost data of Chinese COPD patients 
are extracted from the Guangzhou health insure database. During the simulation, 
both the costs and utilities are annually depreciated at the rate of 3.5%. Results: 
Within 3 years, the Indacaterol group cost 20,089 CNY per capita, and gained 2.151 
QALY or 2.736 LY per capita; the Tiotropium group cost 23,616 CNY per capita and 
gained 2.143 QALY or 2.730 LY per capita. Thus, compared with the Tiotropium group, 
the Indacaterol group saved 3527 CNY and gained more 0.008 QALY or 0.006 LY for 
every patient within 3 years. In the lifetime simulation, Indacaterol group cost 66150 
CNY and gained 8.083 QALY or 10.327 LY per capita, while the Tiotropium group cost 
74915 CNY and gained 8.000 QALY or 10.230 LY per capita. Thus, compared with the 
Tiotropium group, the the Indacaterol group saved 8766 CNY and gained more 0.083 
QALY or 0.097 LY per capita in the lifetime. ConClusions: According to the medical 
costs of COPD patients in Guangzhou, China, the cost-effectiveness of Indacaterol is 
dominant over that of Tiotropium.
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bACkgRound: Asthma is a global health problem and currently it is estimated 
that 300 million people are affected. The aim of asthma treatment is to achieve 
and maintain clinical control. objeCtives: Conduct a cost-effectiveness analy-
sis of budesonide/formoterol as maintenance and reliever therapy for treatment 
of moderate or severe persistent bronchial asthma. Methods: A cost-effective-
ness analysis was performed using a decision tree that compares two treatment 
alternatives: budesonide/formoterol (maintenance and reliever) vs. salmeterol/
fluticasone (maintenance) plus salbutamol (reliever). Efficacy data was obtained 
from scientific literature and direct medical costs was obtained from institutional 
sources. A deterministic and probabilistic sensibility analysis was performed to 
determine the robustness of the model. Two measures of effectiveness were used: 
Life Years Gained without hospitalization (LYGh) and Life Years Gained without 
severe exacerbation (LYGse). Results: Budesonide/formoterol increases the time 
free from hospitalization (49.92 vs. 48.88 weeks) with an ICER (Incremental Cost-
Effectiveness Ratio) of $7,541.51and the free-time of severe exacerbations (41.08 
vs. 37.96 weeks) with an ICER of $3,322.86; both below the willingness to pay set in 
Mexico (1 GDP per capita: $10,047.00).The sensibility analysis showed consistency 
in results: budesonide/formoterol has a probability of 60% of being cost-effective in 
case of LYGh and 90% with LYGse efficacy measure vs. salmeterol/fluticasone under 
threshold ratio. ConClusions: The use of budesonide/formoterol as maintenance 
and reliever therapy is a cost-effective treatment in the Mexican Health system 
compared to salmeterol/fluticasone plus salbutamol reducing the time without a 
severe exacerbation and time in hospitalization.
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objeCtives: This study presents a cost effectiveness of tiotropium compared to 
salmeterol or ipratropium for patients with chronic obstructive pulmonary disease 
(COPD) in Taiwan. Methods: A medical reimbursement claims databases from 
Taiwan’s National Health Insurance were used. National Health Insurance enroll-
ees who had an index event of at least one prescription claim (index medication) 
for either tiotropium, salmeterol or ipratropium during the study period (January 
1,2002-December 31,2006) and met all eligibility criteria were classified into one of 
three cohorts according to their medication use. Utilization and cost data of the 1-year 
post-index period was extracted from these 3 cohorts and used as a cost param-
eter. A published COPD probabilistic Markov model was adapted to compare the cost 
effectivenesss of tiotropium with salmeterol or ipratropium. Results: The study 
population included 3646patients (n= 1559 tiotropium cohort, n= 169 salmeterol, 
n= 1918 ipratropium).The estimated mean annual cost per patient on tiotropium was 
NT49581, on salmeterol was NT45039, and on ipratropium was NT36645.Tiotropium 
patients have better quality-adjusted life years across all comparisons. The probability 
of tiotropium being cost effective ranged from 20% to 30% at a willingness-to-pay 
of NT0 per QALY and reached at least a 70% at a willingness-to-pay of NT600000 
per QALY across comparisons. ConClusions: Tiotropium is more expensive than 
salmeterol or ipratropium in Taiwan’s National Health Insurance. Tiotropium may 
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objeCtives: To compare real-world health care resource utilization (HCRU) and 
health care costs among patients initiated roflumilast compared to those initi-
ated other chronic obstructive pulmonary disease (COPD) medications. Methods: 
A retrospective database analysis was performed using LifelinkTM Health Plan 
Claims Database. We included patients with a diagnosis of COPD who initiated 
roflumilast (roflumilast group) or any other ≥ 3 COPD maintenance drugs (non-
roflumilast group) between May 1, 2011 and December 31, 2012. Patients must have 
been enrolled for 12 months prior to (baseline period) and 3 months after (follow-
up period) the initiation date, be ≥ 40 years old, not corticosteroid-dependent, and 
without asthma diagnosis at baseline. Office and emergency department (ED) visits, 
hospitalizations, and total health care costs were compared between study groups 
using nonparametric Wilcoxon rank-sum test. Difference-in-difference (DID) mod-
els were used to compare the change from baseline in hospitalizations and costs 
between groups while adjusting for baseline differences. Results: During the base-
line period, patients in the roflumilast group (N= 710) had significantly more office 
visits, ED visits, hospitalizations, and greater total costs than patients in the non-
roflumilast group (N= 13,501). The changes from baseline were: monthly frequency of 
office visits (0.081 in roflumilast vs 0.122 in non-roflumilast group; p= 0.01), ED visits 
(0.009 vs 0.007; p= 0.80), hospital admissions (0.002 vs 0.005; p= 0.02), and monthly 
costs ($432 vs $522; p= 0.34). After controlling for key covariates using DID models, 
roflumilast was associated with numerically lower hospital admissions (β = -0.003, 
p= 0.57) and total costs (β = -116, p= 0.62). ConClusions: Smaller increase in office 
visits, hospitalizations and total costs during follow-up from baseline was observed 
in roflumilast vs non-roflumilast group. A longer follow-up time may be needed to 
assess potential improvement in these economic outcomes.
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objeCtives: The cost of medicine is an important factor in any disease treatment. 
Strengthening health systems to provide such interventions at affordable cost to 
all children will save many lives. The present study was carried out to determine 
the total direct cost associated with the treatment of most commonly occurring ill-
ness in children. Methods: The study was carried out prospectively at a pediatric 
outpatient clinic over a period of 1 year in children (< 18 years of age). The data in 
the prescriptions of patients were captured at the time of consultation. The cost 
of treatment were calculated for three most commonly occurring diseases upper 
respiratory tract infection (URTI), acute gastroenteritis (AGE) and reactive airways 
disease (RAD). Results: A total of 2902 patients were included in the study. URTI 
(1078, of total patients) were found to be the most commonly occurring disease in 
children followed by AGE and RAD (468 and 332 patients, respectively). The aver-
age number of drug utilized for the treatment of RAD, AGE and URTI were found 
to be (3.3±0.4, 3.3±0.2 and 3.4±0.4, respectively). The average cost of treatment for 
RAD was found to be INR416±19, followed by INR184±3 and INR120±2 for AGE and 
URTI, respectively (1USD= approx INR62). Fifty seven percent of the drugs in AGE 
were prescribed from the National List of Essential Medicine (NLEM), while drugs 
prescribed from NLEM in RAD and URTI were (49% and 38%, respectively). In URTI 
maximum cost were spent on the use of Cough and Cold combinations (42%, of total 
cost spent on all drugs). While in RAD and AGE maximum cost were spent on the use 
of Steroids and Probiotics ( 33% and 43%, respectively). ConClusions: URTI were 
found to be the most commonly occurring illness in children. RAD treatment was 
found to be the most costly treatment among all. These findings help in building 
evidence regarding the cost of treatment for different childhood illness.
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objeCtives: To evaluate the cost-effectiveness of Glycopirronium (once daily) com-
pared to tiotropium bromide and fixed dose combinations of Formoterol/budesonide 
and Salmeterol/fluticasone for the treatment of COPD from the Colombian Health Care 
system perspective. Methods: A Markov model was designed considering health´s 
state according to GOLD 2010 classification for COPD into mild, moderate, severe and 
very severe. The absorbing state was death. The first four stages include the possibil-
ity of presenting or not a severe exacerbation. Efficacy, based on the initial improve-
ment on FEV1, and outcomes measures were estimated by meta-analysis of published 
studies. Cycles were 3-month and the time horizon was 5 years. Discount rate for 
costs and benefits was 5% per year. Effectivity was evaluated by QALYs according to 
COPD severity. Health costs were determined from medical records from a third level 
university Hospital, from the official Colombian medication database (SISMED) and 
from estimations based on the GOLD guide recommendations for care. A probabilistic 
sensitivity analysis (PSA) was performed using the Montecarlo method. Results: An 
analysis of LYG and QALY showed that Glycopirronium was dominant compared to tio-
tropium and formoterol/budesonide and was inconclusive for salmeterol/fluticasone. 
